These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12833881)

  • 1. [Eczematous reactions after intravenous immunoglobulin therapy in two patients with Guillain-Barré syndrome and a patient with Miller Fisher syndrome].
    Tada M; Tada M; Ishiguro H; Yagi E; Hirota K
    No To Shinkei; 2003 May; 55(5):401-5. PubMed ID: 12833881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain-Barré syndrome.
    Rhee DY; Park GH; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
    J Eur Acad Dermatol Venereol; 2009 May; 23(5):602-4. PubMed ID: 18761548
    [No Abstract]   [Full Text] [Related]  

  • 3. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy.
    Gerstenblith MR; Antony AK; Junkins-Hopkins JM; Abuav R
    J Am Acad Dermatol; 2012 Feb; 66(2):312-6. PubMed ID: 21601310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature.
    Vecchietti G; Kerl K; Prins C; Kaya G; Saurat JH; French LE
    Arch Dermatol; 2006 Feb; 142(2):213-7. PubMed ID: 16490849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy.
    Shin IS; Baer AN; Kwon HJ; Papadopoulos EJ; Siegel JN
    Arthritis Rheum; 2006 May; 54(5):1429-34. PubMed ID: 16645971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Miller fisher variant of guillain-barre syndrome requiring a cardiac pacemaker in a patient on tacrolimus after liver transplantation.
    Kaushik P; Cohen AJ; Zuckerman SJ; Vatsavai SR; Pepper JS; Banda VR; Eason JD; Loss GE; Kaushik R
    Ann Pharmacother; 2005 Jun; 39(6):1124-7. PubMed ID: 15855240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ataxic Guillain-Barré syndrome with delayed facial diplegia].
    Atsumi M; Kitaguchi M; Chimoto Y; Nishikawa S; Mineta H; Nakasaka Y; Tanaka H; Susuki K
    Rinsho Shinkeigaku; 2003 Sep; 43(9):548-51. PubMed ID: 14727561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.
    Brazzelli V; Grassi S; Savasta S; Ruffinazzi G; Carugno A; Barbaccia V; Marseglia GL; Borroni G
    Int J Immunopathol Pharmacol; 2014; 27(1):127-30. PubMed ID: 24674688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guillain-Barré syndrome in childhood].
    Kollár K; Liptai Z; Rosdy B; Móser J
    Ideggyogy Sz; 2009 Nov; 62(11-12):399-404. PubMed ID: 20025130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome.
    Chamouni P; Tamion F; Gueit I; Girault C; Lenain P; Varin R; Czernichow P
    Transfus Apher Sci; 2003 Apr; 28(2):117-24. PubMed ID: 12679114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency.
    Oczko-Walker M; Manousakis G; Wang S; Malter JS; Waclawik AJ
    J Clin Neuromuscul Dis; 2010 Dec; 12(2):55-61. PubMed ID: 21386771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
    França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The therapeutic efficacy in Fisher syndrome].
    Koyama K; Dei F; Koyano S; Suzuki Y
    No To Shinkei; 2005 Feb; 57(2):149-52. PubMed ID: 15856762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulins-induced eczematous eruption: a long-term follow-up study.
    Cohen Aubart F; Barete S; Amoura Z; Francès C; Lyon-Caen O; Lebrun-Vignes B
    Eur J Intern Med; 2009 Jan; 20(1):70-3. PubMed ID: 19237096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    Korinthenberg R; Schessl J; Kirschner J; Mönting JS
    Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of idiopathic inflammatory neuropathies.
    Donofrio PD
    Muscle Nerve; 2003 Sep; 28(3):273-92. PubMed ID: 12929187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Posterior reversible encephalopathy syndrome and stroke after intravenous immunoglobulin treatment in Miller-Fisher syndrome/Bickerstaff brain stem encephalitis overlap syndrome.
    Stetefeld HR; Lehmann HC; Fink GR; Burghaus L
    J Stroke Cerebrovasc Dis; 2014 Oct; 23(9):e423-5. PubMed ID: 25149206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset seropositive Isaacs' syndrome after Guillain-Barré syndrome.
    Myers KA; Baker SK
    Neuromuscul Disord; 2009 Apr; 19(4):288-90. PubMed ID: 19303775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guillain-Barre syndrome and its frontiers].
    Azulay JP; Verschueren A; Attarian S; Pouget J
    Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S21-6. PubMed ID: 12690657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.